---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-022400"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T12:34:42.435183+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bioventus Q1 revenue $123.9M, organic +5%; Non-GAAP EPS $0.08, up 33% YoY, guidance reaffirmed

## Summary
- Q1 revenue $123.9M, reported -4.3% but organic +5.0%; GAAP net loss $0.04/share vs $0.08 prior.
- Non-GAAP EPS $0.08, up 33% YoY; Adjusted EBITDA $19.2M vs $22.6M prior due to divestiture.
- Pain Treatments +3.9%, Surgical Solutions +7.0%, Restorative Therapies -35.3% (reflecting rehab divestiture).
- FY2025 guidance reaffirmed: revenue $560-570M, Adj. EBITDA $112-116M, Non-GAAP EPS $0.64-0.68.
- Entered distribution agreement for XCELL PRP system; added new senior leaders.

## SEC filing metadata
- accession: 0001628280-25-022400
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828025022400/0001628280-25-022400-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828025022400/bvs-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-022400
- JSON: https://secwatch.observer/filing/0001628280-25-022400.json
- Plain text: https://secwatch.observer/filing/0001628280-25-022400.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.